Development of mRNA Rabies Vaccine

Abstract

Rabies is a deadly zoonotic disease predominantly caused by the Rabies Virus (RABV) and is responsible for nearly 100% fatality rates upon symptom onset. The disease is primarily transmitted to humans via dog bites, contributing to 99% of cases worldwide. Post-Exposure Prophylaxis (PEP), which includes vaccination, remains essential to prevent rabies after exposure. Traditional vaccines, though effective, are resource-intensive in terms of production cost and time. mRNA vaccine technology offers an innovative platform characterized by rapid development, scalability, and potential cost reduction. Recent advancements have refined mRNA structural modifications and delivery systems, positioning these vaccines as strong contenders in the fight against rabies. Current clinical and preclinical evaluations of mRNA rabies vaccines indicate their potential to surpass conventional vaccines, offering improved efficacy and convenience. This review discusses the latest developments in mRNA rabies vaccines and their advantages over traditional approaches.